or Try an Advanced Search...

    Technical Analysis for NVCR - NovoCure Limited

    Grade Last Price % Change Price Change
    F 14.87 1.43% 0.21
    NVCR closed up 1.43 percent on Thursday, October 10, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 1
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NVCR trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup 1.43%
    Stochastic Buy Signal Bullish 1.43%
    Wide Bands Range Expansion 1.43%
    Oversold Stochastic Weakness 1.43%
    Pocket Pivot Bullish Swing Setup 1.43%
    Wide Bands Range Expansion 1.43%
    Oversold Stochastic Weakness 1.43%
    NR7 Range Contraction 1.78%
    Older End-of-Day Signals for NVCR ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 15 hours ago
    Possible NR7 about 17 hours ago
    Slingshot Bearish Entry about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NVCR Chart by TradingView
    Basic chart:

    Profile

    NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
    Classification
    Sector: Healthcare
    Industry: Medical Instruments & Supplies
    Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Small Cell Lung Cancer Blastoma Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma

    Is NVCR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 9 NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
    Oct 1 Novocure to Report Third Quarter 2024 Financial Results
    Sep 9 Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
    Sep 6 Why NovoCure Stock Dived by 13% This Week
    Sep 3 NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor
    Sep 3 Novocure names Ashley Cordova as CEO
    Sep 3 Novocure Announces Planned CEO Transition
    Aug 28 Novocure to Participate in 2024 Wells Fargo Healthcare Conference
    Aug 16 Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
    Aug 14 Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
    See more NVCR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.735
    52 Week Low 10.87
    Average Volume 895,869
    200-Day Moving Average 16.72
    50-Day Moving Average 17.42
    20-Day Moving Average 16.09
    10-Day Moving Average 14.97
    Average True Range 0.88
    RSI (14) 37.89
    ADX 21.25
    +DI 13.06
    -DI 23.92
    Chandelier Exit (Long, 3 ATRs) 16.22
    Chandelier Exit (Short, 3 ATRs) 16.81
    Upper Bollinger Bands 18.75
    Lower Bollinger Band 13.42
    Percent B (%b) 0.27
    BandWidth 33.08
    MACD Line -0.85
    MACD Signal Line -0.78
    MACD Histogram -0.0643
    Fundamentals Value
    Market Cap 1.59 Billion
    Num Shares 107 Million
    EPS -1.86
    Price-to-Earnings (P/E) Ratio -7.99
    Price-to-Sales 3.35
    Price-to-Book 4.16
    PEG Ratio -0.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.73
    Resistance 3 (R3) 15.64 15.27 15.58
    Resistance 2 (R2) 15.27 15.05 15.31 15.53
    Resistance 1 (R1) 15.07 14.92 15.17 15.16 15.49
    Pivot Point 14.70 14.70 14.75 14.74 14.70
    Support 1 (S1) 14.50 14.48 14.60 14.59 14.25
    Support 2 (S2) 14.13 14.35 14.17 14.21
    Support 3 (S3) 13.93 14.13 14.16
    Support 4 (S4) 14.02